Quarterly report · Q1
2372.TEDINET S100OU1N
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥15.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.4bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥354m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥439m | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥440m | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥258m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥255m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥28.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥21.8bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥17.2bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥16.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.0bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥10.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥88.37 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥162.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.48 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥88.22 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥162.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.42 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 38.9% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.3% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 62
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-06-30 | ¥23m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-06-30 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥19m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-06-30 | −¥45m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥357m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥364m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥385m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥374m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥10m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥42m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥75m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥61m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥468m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥241m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥226m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥36m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥24m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥337m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥5.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥4.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥357m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-06-30 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-06-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-06-30 | −¥60m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥217m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥217m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥303m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥166m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥164m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1m |
| jpcrp040300-q1r_E05352-000Advanced Medicinal Treatmentreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥162m |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.1bn |
| jpcrp040300-q1r_E05352-000CROreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥16m |
| jpcrp040300-q1r_E05352-000CROreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥71m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥390m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥228m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥161m |
| jpcrp040300-q1r_E05352-000Medical Supportreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥21m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E05352-000SMOreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥35m |
| jpcrp040300-q1r_E05352-000SMOreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥787m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥3.4bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥215m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥717m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥217m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥657m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 404
| Item | Context | Value | Unit |
|---|---|---|---|
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所（プライム市場） | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら制限のない当社における標準となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)㈱アイロムグループ | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都千代田区富士見二丁目10番２号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income single statement (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes additional information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that quarterly statement of cash flows has not been prepared (text) | CurrentYTDDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |